Clinical and Medical Case Reports

Kawasaki disease, an acute inflammatory vasculitis, affects children <5 years old. Coronary artery aneurysms constitute a serious complication of the disease. Both genetic factors and hematological parameters (e.g., mean platelet volume-to-lymphocyte ratio) have been implicated in the development of Kawasaki disease and coronary artery aneurysms. We explored the role of rs13017968, a single nucleotide polymorphism in SLC8A1, and of the mean platelet volume-to-lymphocyte ratio in Kawasaki disease and coronary artery aneurysms.

This single-center, case-control study included children with Kawasaki disease treated in our clinic and healthy children registered in the emergency unit. All patients received intravenous immunoglobulin upon diagnosis. Primary outcomes included rs13017968 frequency and the mean platelet volume-to-lymphocyte ratio in patients (with/without coronary artery aneurysms) and healthy children. Secondary outcomes included the mean platelet volume-to-lymphocyte ratio before and after intravenous immunoglobulin in patients (with/without coronary aneurysms) and correlation of the mean platelet volume-to-lymphocyte ratio with inflammation markers, age, and sex.

Overall, 107 healthy children and 59 patients (mean age: 139.38 months vs 37.36 months) were analyzed. Coronary aneurysms developed in 33.9% of the patients. No statistically significant association was detected between rs13017968 and occurrence of Kawasaki disease or coronary aneurysms. The mean platelet volume-to-lymphocyte ratio was significantly lower in patients than in healthy children and significantly decreased after therapy. No significant interaction was found between the mean platelet volume-to-lymphocyte ratio and coronary aneurysms. The only significant associations were between occurrence of coronary aneurysms and sex and between age and the mean platelet volume-to-lymphocyte ratio (before and after therapy) in patients.

Although our results do not support an association of rs13017968 with Kawasaki disease or coronary aneurysms, the relatively small sample size should be considered. The mean platelet volume-to-lymphocyte ratio, age, and sex appear as significant factors in Kawasaki disease and coronary artery aneurysms. Therefore, larger scale studies are warranted.

Tumour Regressive Grade (TRG), margins and histopathology grade are the way to reach a strategy for addition of adjuvant chemotherapy or not, however lack of solid date about the exact benefit of the sole adjuvant therapy makes it very challenging, so the patients' decisions are very considerable in such cases, especially with high risk features; high TRG, positive margins and poor performance status, as the benefits of pre surgical chemotherapy may not be so clear. High TRG score and borderline performance status may be factors behind a decision to stop treatment after the surgery.

Vestibular schwannoma or acoustic neuroma is a benign, slow-growing tumor that originates in the Schwann cells, where it eventually compresses the nerve and enlarges the internal acoustic meatus. The present case report presents a patient that arrives at the otorhinolaryngology service with complaints of tinnitus, with no other evident alterations and the imaging exam revealed a voluminous lesion in the left point-cerebellar angle. The methodology used for the research was a case study, with the objective of condensing the case and bringing up its most common radiological findings, based on bibliographic studies. Magnetic resonance imaging is of utmost importance for the treatment and proper diagnosis of the patient with suspected vestibular schwannoma.

Advanced cervical cancer has a poor prognosis and few effective therapy options. However, immunotherapy has been approved by the FDA and has shown promising results for patients with cervical cancer. In this report, we present the case of a patient with stage IIIC1 cervical cancer who exhibited a positive response to a combination of Camrelizumab and Apatinib after radio-chemotherapy. Our findings suggest that the combination of Camrelizumab and Apatinib may provide a valuable therapeutic option for advanced cervical cancer patients who do not respond to radiochemotherapy alone.